دورية أكاديمية
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
| العنوان: | Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1. |
|---|---|
| المؤلفون: | Lasrado N; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Rössler A; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Rowe M; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Collier AY; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Barouch DH; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: dbarouch@bidmc.harvard.edu. |
| المصدر: | Vaccine [Vaccine] 2024 Apr 02; Vol. 42 (9), pp. 2117-2121. Date of Electronic Publication: 2024 Mar 07. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam, The Netherlands : Elsevier Science Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983- |
| مواضيع طبية MeSH: | COVID-19*, Humans ; SARS-CoV-2/genetics ; Spike Glycoprotein, Coronavirus/genetics ; Amino Acids ; Antibodies, Neutralizing ; Antibodies, Viral |
| مستخلص: | A new highly mutated Omicron subvariant BA.2.87.1 has recently been identified with over 30 amino acid mutations in the Spike protein compared with BA.2, BA.5, XBB.1.5, and JN.1 variants. Mutiple mutations in BA.2.87.1 are located in the N-terminal domain (NTD) rather than in the receptor binding domain (RBD) of the Spike protein. We evaluated neutralizing antibody (NAb) responses to BA.2.87.1 because of its highly mutated sequence and its unique NTD region. Our data show that NAb responses to BA.2.87.1 were lower than to BA.2 but higher than to JN.1, suggesting that BA.2.87.1 is not a further antibody escape variant compared with other currently circulating variants. Moreover, XBB.1.5 mRNA boosting increased NAb titers to all variants tested including BA.2.87.1. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024. Published by Elsevier Ltd.) |
| فهرسة مساهمة: | Keywords: BA.2.87.1; Neutralizing antibody; Omicron; SARS-CoV-2; mRNA |
| المشرفين على المادة: | 0 (Spike Glycoprotein, Coronavirus) 0 (Amino Acids) 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (spike protein, SARS-CoV-2) |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20240308 Date Completed: 20240408 Latest Revision: 20240408 |
| رمز التحديث: | 20240408 |
| DOI: | 10.1016/j.vaccine.2024.03.007 |
| PMID: | 38458874 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-2518 |
|---|---|
| DOI: | 10.1016/j.vaccine.2024.03.007 |